RxDoctor Payments Data

Ravi Shah, MD

Internal Medicine · Norcross, GANPI 1215381710

Payments from drug & device makers

$3,005in general payments, 2019–2025

Across 92 payments — averaging $32.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Summit Surgical Corp.$1K
  • Novo Nordisk$266
  • AbbVie$206
  • Abbott$204
  • Lilly USA, LLC$197
  • AstraZeneca$188
  • plus $745 from 17 others

What the payments were for

  • Food & beverage$1,79460%
  • Education$1,21240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,005 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$113,346
Medicare patients
286
Services billed
1,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide117$131,823
OzempicSemaglutide78$101,847
Trelegy ElliptaFluticasone/Umeclidin/Vilanter112$78,953
JardianceEmpagliflozin60$76,569
EliquisApixaban32$48,538
TrulicityDulaglutide40$43,312
JanuviaSitagliptin Phosphate19$27,162
FarxigaDapagliflozin Propanediol15$20,748
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$11,020
LinzessLinaclotide12$8,773
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,220
SymbicortBudesonide/Formoterol Fumarate14$4,117
Albuterol Sulfate HfaAlbuterol Sulfate107$3,059
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,779
Gabapentin135$2,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$197$175,135157 claims
Novo NordiskOzempic$266$101,84778 claims
GSKTrelegy Ellipta, Shingrix$146$81,425123 claims
PfizerEliquis$30$48,53832 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$188$35,88541 claims
MerckJanuvia$29$27,16219 claims
AbbVieLinzess$206$8,77312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Norcross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →